(TheNewswire)
LONDON, ON - TheNewswire - December 2 , 2021 - Sernova Corp . (TSXV:SVA)(FSE/XETRA:PSH)(OTC:SEOVF), a leadingclinical-stage company focused on regenerative medicine therapeutics,is pleased to announce that Frank Holler, member and chairmanof the Sernova board of directors, will assume a new role of ExecutiveChair in order to augment the current leadership team and furthersupport the Company’s evolving corporate and R&D activities andobjectives.
“Frank Holler is an experienced veteran in the biotech industry andI look forward to leveraging his expertise and experience to build onour momentum at the forefront of the regenerative therapeuticsspace,” said Dr. Philip Toleikis, President & CEO.
Mr. Holler added, “With our success to date, the Sernova Board ofDirectors believes we are at a critical juncture in the Company’smaturation as we manage the growth of our clinical and pre-clinicalprograms, progress our multiple partnering relationships and leveragecapital markets opportunities. With these additional responsibilities,I am thrilled to lend executive expertise to our current managementand look forward to working even more closely with Dr. PhilipToleikis, and his leadership team to achieve key corporate objectivesfocused on the creation and realization of additional shareholdervalue.”
Mr. Holler is presently President & CEO of Ponderosa Capital Inc.and has previously held Chair or CEO roles at Lions Capital Corp.,Xenon Pharmaceuticals, Inc. and ID Biomedical Corporation. He was alsoa founding director of Angiotech Pharmaceuticals, Inc. Prior to hisexperiences in biotechnology and healthcare, Mr. Holler was aninvestment banker with Merrill Lynch Canada and Wood Gundy, Inc. (nowCIBC World Markets).
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutictechnologies using an implantable medical device and immune protectedtherapeutic cells (i.e., human donor cells, corrected human cells andstem cell-derived cells) to improve the treatment and quality of lifeof people with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASE CONTACT:
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events, including results of clinical trials, andare based on information currently available to management on the datesuch statements were made. Many factors could cause Sernova’s actualresults, performances, or achievements to not be as anticipated,estimated or intended or to differ materially from those expressed orimplied by the forward-looking statements contained in this newsrelease. Many of the factors are beyond our control, including thosecaused by, related to, or impacted by the novel coronavirus pandemic.Investors should consult the company’s quarterly and annual filingsavailable on www.sedar.com for additional information on risks anduncertainties relating to the forward-looking statements. Sernovaexpressly disclaims any intention or obligation to update or reviseany forward-looking statements, whether as a result of newinformation, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.